肉毒毒素化学去神经术治疗膀胱过度活动症的过去、现在与未来
本文系统综述2000年3月至2016年3月间关于onabotulinumtoxin A膀胱化学去神经术的临床前与临床研究,重点讨论膀胱内注射的局限性及未来无注射给药途径。多项大型多中心随机对照试验显示膀胱逼尿肌内注射安全有效;脂质体包裹的onabotulinumtoxin A在多中心安慰剂对照研究中减少排尿频率和尿急,但未显著减少急迫性尿失禁发作。
要点
- 逼尿肌内注射onabotulinumtoxin A的疗效与安全性受注射体积和深度影响。
- 脂质体包裹onabotulinumtoxin A可增强毒素活性并减少降解。
- 无注射给药方式仅影响膀胱传入神经,而逼尿肌内注射同时影响传入和传出神经。
核心结论
- 多项大型多中心随机对照试验报告逼尿肌内注射onabotulinumtoxin A是安全有效的治疗方法。
- 需进一步研究开发更好的给药平台,以克服逼尿肌内注射的缺点、提高患者接受度并降低治疗费用。
研究设计与样本
- 系统综述纳入2000年3月至2016年3月发表的关于onabotulinumtoxin A治疗神经源性膀胱和难治性特发性膀胱过度活动症的经同行评议基础与临床研究。
- 两名研究者独立筛选125篇英文文献,从MEDLINE数据库和美国泌尿外科学会年会摘要中识别onabotulinumtoxin A给药的对照研究。
- 综述形成超过50篇与无注射onabotulinumtoxin A化学去神经术方法相关的证据基础。
主要发现
- 逼尿肌内注射onabotulinumtoxin A治疗膀胱过度活动症的疗效和安全性对注射体积和深度敏感。
- 硫酸鱼精蛋白或二甲基亚砜造成尿路上皮剥脱、脂质体包裹onabotulinumtoxin A及其他物理方法正在被研究,以增加毒素渗透性并避免逼尿肌内注射。
- 脂质体包裹onabotulinumtoxin A可增强毒素活性并减少其降解。
- 脂质体包裹onabotulinumtoxin A的安全性和有效性已在多中心安慰剂对照研究中测试;该治疗成功减少排尿频率和尿急,但未显著减少急迫性尿失禁发作。
局限性
- 需进一步研究开发更好的给药平台,以克服逼尿肌内注射的缺点、提高患者接受度并降低治疗费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We systematically reviewed preclinical and clinical studies on bladder chemodenervation with onabotulinumtoxin A to highlight current limitations and future drug delivery approaches. MATERIALS AND METHODS: We identified peer reviewed basic and clinical research studies of onabotulinumtoxin A in the treatment of neurogenic bladder and refractory idiopathic overactive bladder published between March 2000 and March 2016. Paired investigators independently screened 125 English language articles to identify controlled studies on onabotulinumtoxin A administration in the MEDLINE® database and abstracts presented at annual American Urological Association meetings. The review yielded an evidence base of more than 50 articles relevant to the approach of injection-free onabotulinumtoxin A chemodenervation. RESULTS: The efficacy and safety of intradetrusor injection of onabotulinumtoxin A for the treatment of overactive bladder are sensitive to injection volume and depth, and this issue has motivated researchers to study injection-free modes of drug delivery into the bladder. Urothelial denudation with protamine sulfate or dimethyl sulfoxide, liposome encapsulated onabotulinumtoxin A and other physical approaches are being studied to increase toxin permeability and avoid intradetrusor injections. Liposome encapsulated onabotulinumtoxin A enhances toxin activity while reducing its toxin degradation. The safety and efficacy of liposome encapsulated onabotulinumtoxin A were tested in a multicenter, placebo controlled study. Although this treatment successfully reduced urinary frequency and urgency, it did not significantly reduce urgency urinary incontinence episodes. CONCLUSIONS: Intradetrusor injection of onabotulinumtoxin A is a safe and effective treatment as reported in several large multicenter, randomized controlled trials. Injection of the toxin into the bladder wall impairs afferent and efferent nerves, but injection-free drug delivery approaches only impair the bladder afferent nerves. Further studies are needed to develop better drug delivery platforms that overcome the drawbacks of intradetrusor injection, increase patient acceptance and reduce treatment costs.
引用
- Tyagi P, Kashyap M, Yoshimura N, et al. Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder. J Urol. 2016. PMID: 27871929. doi:10.1016/j.juro.2016.11.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。